The role of JAK2 inhibitors in MPNs 7 years after approval

This article takes a look back at the progress of JAK2 inhibitors in the treatment of MPNs since their approval 7 years ago and discusses the current unmet needs, including defining ruxolitinib failure and designing new trials.

Blood